Indivior Pharmaceuticals (INDV) Debt to Equity (2021 - 2026)

Indivior Pharmaceuticals' Debt to Equity history runs 6 years deep, the most recent figure standing at -$3.38 for Q1 2026.

• In Q1 2026, Debt to Equity fell 192.36% year-over-year to -$3.38; the TTM figure through Mar 2026 stood at -$3.38 (down 192.36% YoY), while the FY2025 annual figure was -$3.26, down 229.42% from the prior year.
• Debt to Equity was -$3.38 for Q1 2026 at Indivior Pharmaceuticals, down from -$3.26 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of -$0.99 in Q4 2024 to a low of -$16.0 in Q4 2022.
• Historically, Debt to Equity has averaged -$3.61 across 5 years, with a median of -$1.43 in 2025.
• The sharpest annual moves came in 2022 and 2023: Debt to Equity tumbled 900.0% in 2022, then soared 91.85% in 2023.
• A 5-year view of Debt to Equity shows it stood at -$16.0 in 2022, then jumped by 91.85% to -$1.3 in 2023, then climbed by 24.24% to -$0.99 in 2024, then plunged by 229.42% to -$3.26 in 2025, then dropped by 3.68% to -$3.38 in 2026.
• The last three Debt to Equity figures came in at -$3.38 (Q1 2026), -$3.26 (Q4 2025), and -$1.56 (Q3 2025), per Business Quant data.